Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 8
2018 10
2019 11
2020 4
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: rofi e. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Clinical pharmacology of intravitreal anti-VEGF drugs.
Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Fogli S, et al. Among authors: rofi e. Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Eye (Lond). 2018. PMID: 29398697 Free PMC article. Review.
Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Del Re M, et al. Among authors: rofi e. Pharmacogenomics. 2017 Jun;18(8):755-756. doi: 10.2217/pgs-2017-0065. Epub 2017 Jun 8. Pharmacogenomics. 2017. PMID: 28593824
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Del Re M, et al. Among authors: rofi e. Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464099 Free PMC article. Review.
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R. Del Re M, et al. Among authors: rofi e. Crit Rev Oncol Hematol. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. Crit Rev Oncol Hematol. 2018. PMID: 29650277 Review.
32 results